{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:31:42Z","timestamp":1783531902126,"version":"3.55.0"},"reference-count":53,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"unspecified","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Marengo Therapeutics"},{"name":"Center for Cancer Research, National Cancer Institute"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,10,7]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Immune checkpoint blockade (ICB) treatment, alone or in combination with standard anticancer therapies, has led to important progress in the treatment of head and neck squamous cell carcinoma (HNSCC). Yet, a significant proportion of patients with carcinogen-associated HNSCC (human papillomavirus (HPV)\n                      <jats:sup>\u2212<\/jats:sup>\n                      ) develop disease relapse or progression. Effective treatments for patients who have failed standard of care (SOC) treatment are lacking. STAR0602, a selective, bifunctional T cell agonist comprising an antibody targeting V\u03b26 and V\u03b210 T cell receptors fused to human interleukin-2, has demonstrated clinical activity in anti-programmed death-ligand 1 resistant tumors. A murine surrogate molecule, mSTAR1302, has been shown to induce tumor regression in multiple syngeneic tumor models and enhance antitumor activity in ICB-refractory settings. This study investigates the therapeutic benefit of mSTAR1302 combined with SOC in the mouse oral carcinoma (MOC)1 and MOC2 HNSCC tumor models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>C57BL\/6 mice bearing MOC1 or MOC2 tumors were treated weekly with mSTAR1302, cisplatin, and \u03b1-programmed cell death protein 1 (PD-1) antibody to determine antitumor efficacy and survival benefit. Immune populations and their effector functions were characterized by flow cytometry and cytokine assays. The tumor microenvironment\u2019s immune architecture was analyzed by multiplex immunofluorescence. Gene expression analysis was conducted to gain an understanding of the mechanism of action of the combination therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Combination therapy with mSTAR1302, cisplatin, and \u03b1-PD-1 promoted robust antitumor activity, higher numbers of mice with complete resolution of tumors, and significantly prolonged survival compared with mSTAR1302 monotherapy or SOC treatment in MOC1 and MOC2 tumors. Tumor-free animals from cohorts treated with the combination therapy demonstrated protection against tumor rechallenge and an overall increase in antigen-specific T cells. Tumor growth inhibition was associated with the expansion of V\u03b213 CD8\n                      <jats:sup>+<\/jats:sup>\n                      and CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells, characterized by heightened cytotoxic and effector potentials, in both the tumor and the periphery. The therapeutic effect elicited by the combination therapy was strongly dependent on interferon-\u03b3 expression. Thus, the combination of mSTAR1302 and \u03b1-PD-1 enabled control of tumors that progressed following platinum-containing treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      These findings provide a rationale for the combination of STAR0602 and SOC therapy in the clinical setting for patients with recurrent or metastatic HPV\n                      <jats:sup>\u2212<\/jats:sup>\n                      HNSCC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013158","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:00:15Z","timestamp":1761645615000},"page":"e013158","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Combination of a novel TCR V\u03b2 chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refractory tumor models"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct03765918","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05592626","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02358031","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03765918","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05592626","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06827613","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Francesca","family":"Rosato","sequence":"first","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginette","family":"Santiago-Sanchez","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0273-5647","authenticated-orcid":false,"given":"Kellsye P","family":"Fabian","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R","family":"Padget","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonelle K","family":"Lee","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6586-5804","authenticated-orcid":false,"given":"Clint Tanner","family":"Allen","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Su","sequence":"additional","affiliation":[{"name":"Marengo Therapeutics, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madan","family":"Katragadda","sequence":"additional","affiliation":[{"name":"Marengo Therapeutics, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Moisan","sequence":"additional","affiliation":[{"name":"Marengo Therapeutics, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bayliffe","sequence":"additional","affiliation":[{"name":"Marengo Therapeutics, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5282-3154","authenticated-orcid":false,"given":"James W","family":"Hodge","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"2026052722305243000_13.10.e013158.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2026052722305243000_13.10.e013158.2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026052722305243000_13.10.e013158.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0227-z"},{"key":"2026052722305243000_13.10.e013158.4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21565"},{"key":"2026052722305243000_13.10.e013158.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7"},{"key":"2026052722305243000_13.10.e013158.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02508"},{"key":"2026052722305243000_13.10.e013158.7","unstructured":"Douglas Adkins RH , Yungan T . Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study. American Association for Cancer Research (AACR), Chicago: 2025 ASCO Annual Meeting; 2025"},{"key":"2026052722305243000_13.10.e013158.8","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/OP.24.00041","article-title":"Immunotherapy for Head and Neck Squamous Cell Carcinoma: Present and Future Approaches and Challenges","volume":"20","author":"Orland","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"2026052722305243000_13.10.e013158.9","doi-asserted-by":"crossref","unstructured":"Hsu J , Donahue RN , Katragadda M , et al . A T cell receptor \u03b2 chain\u2013directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity. Sci Transl Med 2023;15. doi:10.1126\/scitranslmed.adi0258","DOI":"10.1126\/scitranslmed.adi0258"},{"key":"2026052722305243000_13.10.e013158.10","doi-asserted-by":"crossref","unstructured":"Vantourout P , Eum J , Conde Poole M , et al . Innate TCR\u03b2-chain engagement drives human T cells toward distinct memory-like effector phenotypes with immunotherapeutic potentials. Sci Adv 2023;9. doi:10.1126\/sciadv.adj6174","DOI":"10.1126\/sciadv.adj6174"},{"key":"2026052722305243000_13.10.e013158.11","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3581"},{"key":"2026052722305243000_13.10.e013158.12","first-page":"A1702","article-title":"1470\u2005START001: a phase 1\/2 study of invikafusp alfa (star0602), a first-in-class tcr \u03b2 chain-targeted bispecific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-pd(l)1","volume":"12(Suppl 3)","author":"Gulley","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026052722305243000_13.10.e013158.13","first-page":"3657","article-title":"Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line","volume":"51","author":"Robbins","year":"1991","journal-title":"Cancer Res"},{"key":"2026052722305243000_13.10.e013158.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol"},{"key":"2026052722305243000_13.10.e013158.15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005921","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors","volume":"11","author":"Kluger","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026052722305243000_13.10.e013158.16","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS18-4557"},{"key":"2026052722305243000_13.10.e013158.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0205"},{"key":"2026052722305243000_13.10.e013158.18","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.4.6.889"},{"key":"2026052722305243000_13.10.e013158.19","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89829","article-title":"The head and neck cancer immune landscape and its immunotherapeutic implications","volume":"1","author":"Mandal","year":"2016","journal-title":"JCI Insight"},{"key":"2026052722305243000_13.10.e013158.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145342","article-title":"Novel Markers to Delineate Murine M1 and M2 Macrophages","volume":"10","author":"Jablonski","year":"2015","journal-title":"PLoS One"},{"key":"2026052722305243000_13.10.e013158.21","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349"},{"key":"2026052722305243000_13.10.e013158.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.01.012"},{"key":"2026052722305243000_13.10.e013158.23","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1758602","article-title":"Endogenous retroviral proteins provide an immunodominant but not requisite antigen in a murine immunotherapy tumor model","volume":"9","author":"Ye","year":"2020","journal-title":"Oncoimmunology"},{"key":"2026052722305243000_13.10.e013158.24","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200003000-00001"},{"key":"2026052722305243000_13.10.e013158.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2019.06.016"},{"key":"2026052722305243000_13.10.e013158.26","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0101"},{"key":"2026052722305243000_13.10.e013158.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30066-3"},{"key":"2026052722305243000_13.10.e013158.28","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34823"},{"key":"2026052722305243000_13.10.e013158.29","doi-asserted-by":"publisher","DOI":"10.1097\/MOO.0b013e3282f495b6"},{"key":"2026052722305243000_13.10.e013158.30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2244"},{"key":"2026052722305243000_13.10.e013158.31","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.7150\/ijbs.58077","article-title":"Therapeutic strategies of different HPV status in Head and Neck Squamous Cell Carcinoma","volume":"17","author":"Sun","year":"2021","journal-title":"Int J Biol Sci"},{"key":"2026052722305243000_13.10.e013158.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.10.001"},{"key":"2026052722305243000_13.10.e013158.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.02.026"},{"key":"2026052722305243000_13.10.e013158.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01323-8"},{"key":"2026052722305243000_13.10.e013158.35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2481"},{"key":"2026052722305243000_13.10.e013158.36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009712","article-title":"Alum-anchored IL-12 combined with cytotoxic chemotherapy and immune checkpoint blockade enhanced antitumor immune responses in head and neck cancer models","volume":"12","author":"Fabian","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026052722305243000_13.10.e013158.37","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0790"},{"key":"2026052722305243000_13.10.e013158.38","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"2026052722305243000_13.10.e013158.39","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1172-6"},{"key":"2026052722305243000_13.10.e013158.40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040"},{"key":"2026052722305243000_13.10.e013158.41","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41416-020-01225-5","article-title":"Overcoming the challenges associated with CD3+ T-cell redirection in cancer","volume":"124","author":"Singh","year":"2021","journal-title":"Br J Cancer"},{"key":"2026052722305243000_13.10.e013158.42","doi-asserted-by":"crossref","first-page":"316","DOI":"10.21037\/tcr-21-2506","article-title":"Granzyme B for predicting the durable clinical benefit of anti-PD-1\/PD-L1 immunotherapy in patients with non-small cell lung cancer","volume":"11","author":"Chung","year":"2022","journal-title":"Transl Cancer Res"},{"key":"2026052722305243000_13.10.e013158.43","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc2777","article-title":"Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy","volume":"6","author":"Nguyen","year":"2020","journal-title":"Sci Adv"},{"key":"2026052722305243000_13.10.e013158.44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.888713"},{"key":"2026052722305243000_13.10.e013158.45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3726"},{"key":"2026052722305243000_13.10.e013158.46","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.ccell.2023.08.004","article-title":"Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression","volume":"41","author":"Topp","year":"2023","journal-title":"Cancer Cell"},{"key":"2026052722305243000_13.10.e013158.47","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT205","article-title":"Abstract CT205: Updated clinical results, recommended phase 2 dose (RP2D) determination and translational study results for START-001: A phase 1\/2 trial of invikafusp alfa, a first-in-class TCR b chain-targeted bispecific antibody in patients with anti-PD(L)1-resistant, antigen-rich solid tumors","volume":"85","author":"Sullivan","year":"2025","journal-title":"Cancer Res"},{"key":"2026052722305243000_13.10.e013158.48","unstructured":"Marengo Therapeutics I . Marengo\u2019s first-in-class invikafusp alfa (STAR0602) receives U.S. FDA fast track designation for treatment of unresectable, locally advanced, or metastatic colorectal cancers with high tumor mutational burden (TMB-H). News Release; 2025. Available: https:\/\/tinyurl.com\/zbcerb9k"},{"key":"2026052722305243000_13.10.e013158.49","unstructured":"Marengo Therapeutics I . Marengo therapeutics announces clinical study collaboration with gilead sciences to evaluate invikafusp alfa (STAR0602) and trodelvy\u00ae in both metastatic TNBC and metastatic HR+\/HER2- breast cancers. News Release; 2024. Available: https:\/\/marengotx.com\/wp-content\/uploads\/2024\/09\/marengo-press-release-clinical-combo-adc-with-gilead-drug-supply.pdf"},{"key":"2026052722305243000_13.10.e013158.50","doi-asserted-by":"publisher","DOI":"10.1177\/0194599812442037"},{"key":"2026052722305243000_13.10.e013158.51","doi-asserted-by":"publisher","DOI":"10.1007\/s10735-009-9228-z"},{"key":"2026052722305243000_13.10.e013158.52","first-page":"473","article-title":"Comparable molecular alterations in 4-nitroquinoline 1-oxide-induced oral and esophageal cancer in mice and in human esophageal cancer, associated with poor prognosis of patients","volume":"27","author":"Yang","year":"2013","journal-title":"In Vivo"},{"key":"2026052722305243000_13.10.e013158.53","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00262-019-02348-2","article-title":"Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma","volume":"68","author":"Ludwig","year":"2019","journal-title":"Cancer Immunol Immunother"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:31:35Z","timestamp":1779946295000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":53,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,28]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/jitc-2025-013158"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013158","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}